ArticleJournal of medical biochemistry2026
Interaction between intestinal microbiota, inflammatory cytokines, and the expression of miR-330-3p and miR-515-5p in patients with ulcerative colitis.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ulcerative colitis (UC) has a complex pathogenesis involving multiple factors. This study aims to explore the interplay among intestinal microbiota, serum inflammatory cytokines, and miR-330-3p, miR-515-5p in UC patients for novel treatment strategies. Methods: The study enrolled 95 healthy controls, 88 UC patients in remission, and 91 in active diseases. Assessments included clinical data, intestinal microbiota detection (using culture methods), serum cytokine measurement (using ELISA assay), and miRNA expression analysis (using RTqPCR). ROC curves evaluated diagnostic value, and multivariate logistic regression identified risk factors. Results: From the control group to UC remission and then to seizure UC, significant decreases were observed in Bifidobacterium, Lactobacillus counts, IL-10 levels, and miR-515-5p expression, while increases were noted in Enterobacteriaceae, Enterococcus counts, IL-6, TNF-<span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">α</span> levels, and miR-330-3p expression (P< 0.05). ROC curve analysis showed improved diagnostic accuracy for UC with the combination of miR-330-3p and miR-515-5p (AUC=0.899, 95% CI: 0.936 -0.978, sensitivity: 92.18%, specificity: 88.42%). miR-515-5p positively correlated with beneficial microbiota and IL-10 (r > 0.5, p<0.001) and negatively with harmful microbiota, IL-6, and TNF-a (r< -0.5, p<0.001); miR-330-3p showed opposite correlations. miR-515-5p, Bifidobacterium, Lactobacillus, and IL-10 were protective factors for UC, whereas miR-330-3p, Enterobacteriaceae, Enterococcus, IL-6, and TNF-<span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">α</span> were risk factors. Conclusions: This study revealed interactions among intestinal microbiota, serum inflammatory cytokines, and miRNAs in UC patients, confirming the potential of miR-330-3p and miR-515-5p in UC diagnosis and assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.